BartsMS....Get your focus onto an Unmet Need

It seems that academic  neuros are essentially only able to target un-met needs, unless they are helping pharma deliver what ever they want. 

Targeting RRMS is difficult, given that there are over 10 different DMT. Ocrelizumab may make headway into active PPMS and cut off that route. Soon we will hear if siponimod affects secondary progressive MS, if it does do we stop doing anything as  all avenues are sewn-up.

Some of you have said "switch focus and do something different".

ProfG has been thinking, DrK has been thinking, but can we get the regulators and neuros to do some thinking? 

If we can, maybe we can do something for people who get missed out of studies.



What do you think? Shall we go for it? 

Can ProfG get pharma and the regulators to bite and show that the EDSS is not the only answer?

Does DrK care, if it brings benefit to pwMS, let's go for it, what do you think ?

Labels: ,